Skip to content
lifestyle.entreprenerd.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
ELI LILLY AND COMPANY
New Phase 3b data show Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
September 30, 2026
Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
September 30, 2026
Lilly’s Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
September 29, 2026
Lilly’s Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
September 29, 2026
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
September 28, 2026
FDA approves Lilly’s Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
September 25, 2026
U.S. Food and Drug Administration (FDA) approves Lilly’s Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
September 24, 2026
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
September 22, 2026
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
September 21, 2026
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
September 15, 2026
1
2
3
…
7
Next Page
→